IRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will participate in a plenary session at the upcoming 18th Congress of the International Xenotransplantation Association (IXA) taking place from September 30–October 3, 2025, in Geneva, Switzerland. Details are as follows:Plenary Session: Immunosuppression, Immune Monitoring, Anti-CD154* Pathway Blockade: How Far do We Need to Go? Lecture Title: 201.2 Anti-CD154 Pathway BlockadeDate: Wednesday, October 1, 2025Time: 10:30 a.m. – 12:00 p.m. CET*CD154 is also known as CD40L or CD40 LigandAbout Eledon Pharmaceuticals and tegoprubartEledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. Follow Eledon Pharmaceuticals on social media: LinkedIn; TwitterInvestor Contact:Stephen JasperGilmartin Group(858) 525 [email protected] Contact:Jenna UrbanCG Life(212) 253 [email protected]: Eledon Pharmaceuticals